News

With this agreement, PharmaNet will have to access potential subjects who are suffering from mild, moderate, or severe impaired renal function. PharmaNet Early Stage Development president Riaz Bandali

In 2002, Amylin had entered into an alliance with Lilly for the global development and commercialization of exenatide, a medicine indicated as a first line treatment for type

Genmed focuses on the delivery of low cost generic pharmaceutical drugs directly to distribution channels. Genmed said prior to the approval it was already approved to distribute 20

Vayacog, a once-daily formulation of phosphatidylserine – omega 3 compound, DHA enriched, is a prescription medical food. Regulated by the US Food and Drug Administration under the Orphan

The approval has been granted for Sativex as an add-on therapy to treat moderate to severe spasticity due to multiple sclerosis (MS) in patients who have not responded

CEN-209, the seventh drug candidate to enter Cancer Research UK’s Clinical Development Partnerships (CDP) scheme, is discovered at the Auckland Cancer Society Research Centre and exclusively licensed to

Specifar is a third-party product developer, with approximately 400 marketing authorizations licensed to third parties for sale in 36 countries, mainly in Europe. It has eight products currently

In working with the MAVERIC team, Recombinant uses its Agile Iterative Development approach to design and prototyping, and delivering production systems in a just-in-time mode to meet the

The study assessed around 168 healthy subjects to investigate the safety and preliminary immunogenicity in the different age groups. The preliminary immunogenicity results demonstrated that the vaccine has